HUTCHMED
HUTCHMED completes enrolment in phase 3 trial for lung cancer
August 21, 2025Research and Development HUTCHMED, Oncology, clinical trial, lung cancer, non-small cell lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use of ORPATHYS (savolitinib) in combination …
NDA in China receives priority review status for lung cancer treatment
January 3, 2025Research and Development China, China National Medical products Administration, HUTCHMED, NDA, Oncology, epidermal growth factor receptor, non-small cell lung cancer, priority review
HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority review for a new drug …
Hutchmed announces phase 3 trial met primary endpoint for primary immune thrombocytopenia treatment
August 21, 2023Research and Development HUTCHMED, Haematology, clinical trial, sovleplenib, thrombocytopenia
Hutchmed has announced that its phase 3 trial ESLIM-01 trial assessing the use of sovleplenib has met its primary endpoint …
Takeda and HUTCHMED’s cancer drug shown to prolong overall survival
June 16, 2023Research and Development HUTCHMED, Oncology, Takeda, colorectal cancer
Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which is being developed by Japanese …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
